A Pilot Study on Imaging of Integrin Αvβ3 with RGD PET/CT in Suspected Lung Cancer Patients

Song Gao,N. Liu,W. Li,Shuqiang Zhao,Xuepeng Teng,Zheng Fu,Xiaoqian Sun,Jie Zheng,Li Ma,Hong Lu,J. Liu,Jin Yu,Shuanghu Yuan

DOI: https://doi.org/10.1016/j.ijrobp.2014.05.1919

2014-01-01

Abstract:Purpose/Objective(s)Angiogenesis is an essential step for tumor development and metastasis. The cell adhesion molecule αvβ3 integrin is a specific marker of tumor angiogenesis and diagnosis. A new tracer,18F-AL-NOTA-PRGD2, denoted as 18F-Alfatide, has been developed for PET imaging of integrin αvβ3. The objective of the present study was to test the safety and explore whether RGD PET/CT can be used in the diagnosis imaging of lung cancer.Materials/MethodsOur Institutional Review Board approved this study and 10 patients with suspected lung cancer on enhanced CT underwent RGD PET/CT examination before surgery. Standard uptake values (SUV) and tumor-to-blood ratio were measured in tumors at 1 hour after injection. Surgery and pathology were performed to confirm the diagnosis.ResultsRGD PET-CT with 18F-Alfatide was performed successfully in all patients and no clinically significant adverse events were observed. One patient with suspected mass was hematoma on pathologic examination and showed low mean SUV(1.43) and low tumor-to-blood ratio (1.18) in the RGD PET imaging. Another patient's lung mass was benign chronic inflammatory lesion with SUV 2.2 and tumor-to-blood ration 2.1 in RGD PET imaging. The other 8 patients' mass were all non-small cell lung cancers, including 3 squamous cell carcinoma and 5 adenocarcinoma, with mean SUV 2.83 ± 0.63 and mean tumor-to-blood ratio 4.28 ± 0.76. Took tumor-to-blood ratio 2.5 as the threshold, RGD PET had both high sensitivity and specificity as 100% in distinguishing non-small cell lung cancer from hematoma and inflammatory lesion in this study.ConclusionsOur results suggest RGD PET-CT with the new tracer 18F-Alfatide is safe and effective. It may be applied to the diagnosis of lung cancer and distinguish it from hematoma and inflammatory lesions. However, it is difficult to clearly differentiate inflammatory from malignant lesions. Further study with a larger number of patients is needed to validate our findings. Purpose/Objective(s)Angiogenesis is an essential step for tumor development and metastasis. The cell adhesion molecule αvβ3 integrin is a specific marker of tumor angiogenesis and diagnosis. A new tracer,18F-AL-NOTA-PRGD2, denoted as 18F-Alfatide, has been developed for PET imaging of integrin αvβ3. The objective of the present study was to test the safety and explore whether RGD PET/CT can be used in the diagnosis imaging of lung cancer. Angiogenesis is an essential step for tumor development and metastasis. The cell adhesion molecule αvβ3 integrin is a specific marker of tumor angiogenesis and diagnosis. A new tracer,18F-AL-NOTA-PRGD2, denoted as 18F-Alfatide, has been developed for PET imaging of integrin αvβ3. The objective of the present study was to test the safety and explore whether RGD PET/CT can be used in the diagnosis imaging of lung cancer. Materials/MethodsOur Institutional Review Board approved this study and 10 patients with suspected lung cancer on enhanced CT underwent RGD PET/CT examination before surgery. Standard uptake values (SUV) and tumor-to-blood ratio were measured in tumors at 1 hour after injection. Surgery and pathology were performed to confirm the diagnosis. Our Institutional Review Board approved this study and 10 patients with suspected lung cancer on enhanced CT underwent RGD PET/CT examination before surgery. Standard uptake values (SUV) and tumor-to-blood ratio were measured in tumors at 1 hour after injection. Surgery and pathology were performed to confirm the diagnosis. ResultsRGD PET-CT with 18F-Alfatide was performed successfully in all patients and no clinically significant adverse events were observed. One patient with suspected mass was hematoma on pathologic examination and showed low mean SUV(1.43) and low tumor-to-blood ratio (1.18) in the RGD PET imaging. Another patient's lung mass was benign chronic inflammatory lesion with SUV 2.2 and tumor-to-blood ration 2.1 in RGD PET imaging. The other 8 patients' mass were all non-small cell lung cancers, including 3 squamous cell carcinoma and 5 adenocarcinoma, with mean SUV 2.83 ± 0.63 and mean tumor-to-blood ratio 4.28 ± 0.76. Took tumor-to-blood ratio 2.5 as the threshold, RGD PET had both high sensitivity and specificity as 100% in distinguishing non-small cell lung cancer from hematoma and inflammatory lesion in this study. RGD PET-CT with 18F-Alfatide was performed successfully in all patients and no clinically significant adverse events were observed. One patient with suspected mass was hematoma on pathologic examination and showed low mean SUV(1.43) and low tumor-to-blood ratio (1.18) in the RGD PET imaging. Another patient's lung mass was benign chronic inflammatory lesion with SUV 2.2 and tumor-to-blood ration 2.1 in RGD PET imaging. The other 8 patients' mass were all non-small cell lung cancers, including 3 squamous cell carcinoma and 5 adenocarcinoma, with mean SUV 2.83 ± 0.63 and mean tumor-to-blood ratio 4.28 ± 0.76. Took tumor-to-blood ratio 2.5 as the threshold, RGD PET had both high sensitivity and specificity as 100% in distinguishing non-small cell lung cancer from hematoma and inflammatory lesion in this study. ConclusionsOur results suggest RGD PET-CT with the new tracer 18F-Alfatide is safe and effective. It may be applied to the diagnosis of lung cancer and distinguish it from hematoma and inflammatory lesions. However, it is difficult to clearly differentiate inflammatory from malignant lesions. Further study with a larger number of patients is needed to validate our findings. Our results suggest RGD PET-CT with the new tracer 18F-Alfatide is safe and effective. It may be applied to the diagnosis of lung cancer and distinguish it from hematoma and inflammatory lesions. However, it is difficult to clearly differentiate inflammatory from malignant lesions. Further study with a larger number of patients is needed to validate our findings.